ALXO - ALX Oncology Publishes Positive Interim Phase 2 ASPEN-06 Evorpacept Clinical Trial Results

2023-10-03 08:13:54 ET

(24/7 MARKET NEWS) – ALX Oncology Holdings Inc., (NASDAQ: ALXO) published, this morning, positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s CD47 blocking therapeutic, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer, representing the results from 54 randomized patients with second and third line gastric/GEJ cancer, including a meaningful number of patients previously treated with ENHERTU® (trastuzumab deruxtecan) and checkpoint inhibitors. The interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment, while the safety profile of evorpacept was consistent with previous clinical trials and was …

The post ALX Oncology Publishes Positive Interim Phase 2 ASPEN-06 Evorpacept Clinical Trial Results appeared first on 24/7 Market News .

For further details see: